Literature DB >> 2301922

Immunoglobulins promote remyelination in the central nervous system.

M Rodriguez1, V A Lennon.   

Abstract

Remyelination of central nervous system axons was promoted by systemic injection of serum immunoglobulin G (IgG) from donor mice hyperimmunized with homogenized spinal cord. In SJL/J mice infected with Theiler's virus, primary demyelination and inflammation in the spinal cord were extensive. Following treatment with IgG to spinal cord homogenate, new myelin synthesis as measured by quantitative morphometry increased sixfold. Cells in areas of remyelination that incorporated [3H]thymidine did not express differentiation markers of macrophages, oligodendrocytes, or astrocytes but were identified by electron microscopic autoradiography as progenitor glial cells. These findings raise the possibility that IgG secreted in demyelinating lesions might have the potential to promote myelin repair.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2301922     DOI: 10.1002/ana.410270104

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  34 in total

1.  New therapeutic perspectives for demyelinating retrobulbar optic neuritis.

Authors:  B Currò Dossi; A Amadori; C Cirafisi; S Lorusso; M Pasquinelli; M G Piscaglia; A Ravasio
Journal:  Ital J Neurol Sci       Date:  1998-02

Review 2.  Outcomes assessment of drug treatment in multiple sclerosis clinical trials.

Authors:  M Malone; B Lomaestro
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

Review 3.  Intravenous immunoglobulin in eye involvement.

Authors:  Zera Tellier
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Multicolor fluorescence in situ hybridization and pulsed field electrophoresis dissect CMT1B gene region.

Authors:  R V Lebo; E D Lynch; J Wiegant; K Moore; M Trounstine; M van der Ploeg
Journal:  Hum Genet       Date:  1991-11       Impact factor: 4.132

Review 5.  Remyelination strategies: new advancements toward a regenerative treatment in multiple sclerosis.

Authors:  Martin Stangel; Corinna Trebst
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

6.  High dose immunoglobulin IV treatment in adrenoleukodystrophy.

Authors:  M Cappa; E Bertini; P del Balzo; P Cambiaso; A Di Biase; S Salvati
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

7.  Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.

Authors:  J H Noseworthy; P C O'Brien; B G van Engelen; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

8.  Myelin basic protein does not have a mitogenic effect on adult oligodendrocytes.

Authors:  G R Moore; S U Kim; E Chang; M Kim
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 9.  Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis.

Authors:  B G van Engelen; D J Miller; K D Pavelko; O R Hommes; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

10.  B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice.

Authors:  Daniel P Ankeny; Zhen Guan; Phillip G Popovich
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.